RayKnowChina Research Map
Shortlist

Cancer

Glioma

胶质瘤

Tumours of the brain and spinal cord that arise from glial cells. They can be benign or malignant; glioblastoma is one type.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
187

with a paper from 2016–2025 or a registered study

cities
67

where those hospitals are

open trials in China
103

ClinicalTrials.gov, 18 Nov 2026

Mainland China accounts for 32% of the world's English-language research papers on glioma, 2021–2025 (24% in 2016–2020), and 10% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

187 hospitals in 67 cities

Order: papers led on glioma, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 8 papers or 1 trial on glioma, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Shanghai17
  2. Beijing14
  3. Guangzhou13
  4. Hangzhou9
  5. Chongqing8
  6. Nanjing6
  7. Zhengzhou6
  8. Jinan5
  9. Xi'an5
  10. Changchun4

Each opens glioma in that city. 57 more cities are in the menu below.

  1. Beijing Tiantan Hospital

    首都医科大学附属北京天坛医院BeijingInternational Department

    307 papers led
  2. 169 papers led
  3. Xiangya Hospital

    中南大学湘雅医院Changsha

    158 papers led
  4. 122 papers led
  5. 106 papers led
    No open trial led
  6. 82 papers led
  7. 78 papers led
  8. 72 papers led
  9. 71 papers led
    No open trial led
  10. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    70 papers led
    No open trial led
  11. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    66 papers led
  12. 63 papers led
    No open trial led
  13. 62 papers led
  14. 61 papers led
    No open trial led
  15. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    61 papers led
  16. 60 papers led
    No open trial led
  17. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    59 papers led
    No open trial led
  18. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    56 papers led
  19. 56 papers led
  20. 56 papers led
  21. 54 papers led
    No open trial led
  22. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    53 papers led
    No open trial led
  23. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    53 papers led
  24. 52 papers led
    No open trial led
  25. 52 papers led
  26. 50 papers led
    No open trial led
  27. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    47 papers led
  28. Xijing Hospital

    空军军医大学西京医院Xi'an

    46 papers led
  29. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    44 papers led
    No open trial led
  30. 44 papers led
    No open trial led
  31. 43 papers led
    No open trial led
  32. 41 papers led
  33. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    40 papers led
    No open trial led
  34. 39 papers led
    No open trial led
  35. 39 papers led
  36. 39 papers led
    No open trial led
  37. 38 papers led
    No open trial led
  38. 35 papers led
    No open trial led
  39. 32 papers led
    No open trial led
  40. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    32 papers led
    No open trial led
  41. Xinhua Hospital

    上海交通大学医学院附属新华医院Shanghai

    32 papers led
    No open trial led
  42. 31 papers led
    No open trial led
  43. 31 papers led
    No open trial led
  44. 31 papers led
    No open trial led
  45. 30 papers led
    No open trial led
  46. Sanbo Brain Hospital

    首都医科大学三博脑科医院Beijing

    30 papers led
  47. Tangdu Hospital

    空军军医大学唐都医院Xi'an

    29 papers led
    No open trial led
  48. 28 papers led
    No open trial led
  49. 26 papers led
  50. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    26 papers led
    No open trial led
  51. 26 papers led
    No open trial led
  52. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    25 papers led
  53. 25 papers led
    No open trial led
  54. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    25 papers led
    No open trial led
  55. Jinling Hospital

    东部战区总医院(金陵医院)Nanjing

    24 papers led
    No open trial led
  56. 24 papers led
    No open trial led
  57. 24 papers led
  58. 23 papers led
    No open trial led
  59. 23 papers led
  60. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    22 papers led
    No open trial led
  61. 22 papers led
    No open trial led
  62. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    22 papers led
    No open trial led
  63. 21 papers led
    No open trial led
  64. 21 papers led
    No open trial led
  65. 21 papers led
    No open trial led
  66. 21 papers led
    No open trial led
  67. 21 papers led
    No open trial led
  68. 21 papers led
  69. Hunan Cancer Hospital

    湖南省肿瘤医院Changsha

    20 papers led
    No open trial led
  70. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    20 papers led
    No open trial led
  71. 19 papers led
    No open trial led
  72. 19 papers led
    No open trial led
  73. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    19 papers led
    No open trial led
  74. 18 papers led
    No open trial led
  75. 18 papers led
    No open trial led
  76. 18 papers led
    No open trial led
  77. Second Hospital of Dalian Medical University

    大连医科大学附属第二医院Dalian

    18 papers led
    No open trial led
  78. 18 papers led
    No open trial led
  79. 17 papers led
    No open trial led
  80. Linyi People's Hospital

    临沂市人民医院Linyi

    17 papers led
    No open trial led
  81. 17 papers led
    No open trial led
  82. 16 papers led
    No open trial led
  83. 16 papers led
    No open trial led
  84. 16 papers led
    No open trial led
  85. 15 papers led
    No open trial led
  86. 15 papers led
    No open trial led
  87. 15 papers led
    No open trial led
  88. Jiangsu Cancer Hospital

    江苏省肿瘤医院Nanjing

    15 papers led
    No open trial led
  89. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    15 papers led
    No open trial led
  90. Tianjin Huanhu Hospital

    天津市环湖医院Tianjin

    15 papers led
  91. 14 papers led
    No open trial led
  92. 14 papers led
    No open trial led
  93. 14 papers led
  94. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    14 papers led
    No open trial led
  95. Harbin Medical University Cancer Hospital

    哈尔滨医科大学附属肿瘤医院Harbin

    14 papers led
    No open trial led
  96. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    14 papers led
    No open trial led
  97. 14 papers led
    No open trial led
  98. Taihe Hospital

    十堰市太和医院Shiyan

    14 papers led
    No open trial led
  99. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    14 papers led
    No open trial led
  100. 14 papers led
    No open trial led
  101. Xinqiao Hospital, Army Medical University

    陆军军医大学第二附属医院(新桥医院)Chongqing

    14 papers led
    No open trial led
  102. 13 papers led
    No open trial led
  103. 13 papers led
    No open trial led
  104. Chongqing General Hospital

    重庆大学附属中心医院(重庆市人民医院)Chongqing

    13 papers led
    No open trial led
  105. 13 papers led
    No open trial led
  106. 13 papers led
    No open trial led
  107. 13 papers led
    No open trial led
  108. Shanghai General Hospital

    上海市第一人民医院Shanghai

    13 papers led
    No open trial led
  109. 13 papers led
    No open trial led
  110. 12 papers led
    No open trial led
  111. 12 papers led
    No open trial led
  112. 12 papers led
    No open trial led
  113. 12 papers led
    No open trial led
  114. Shanghai Tenth People's Hospital

    上海市第十人民医院Shanghai

    12 papers led
    No open trial led
  115. 12 papers led
    No open trial led
  116. 12 papers led
    No open trial led
  117. Zhongda Hospital, Southeast University

    东南大学附属中大医院Nanjing

    12 papers led
    No open trial led
  118. 11 papers led
    No open trial led
  119. 11 papers led
    No open trial led
  120. 11 papers led
    No open trial led
  121. 11 papers led
    No open trial led
  122. 11 papers led
    No open trial led
  123. 11 papers led
    No open trial led
  124. 11 papers led
    No open trial led
  125. 11 papers led
    No open trial led
  126. 11 papers led
    No open trial led
  127. 11 papers led
    No open trial led
  128. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    11 papers led
    No open trial led
  129. 10 papers led
    No open trial led
  130. Changzheng Hospital

    海军军医大学第二附属医院(长征医院)Shanghai

    10 papers led
    No open trial led
  131. Chongqing University Cancer Hospital

    重庆大学附属肿瘤医院Chongqing

    10 papers led
    No open trial led
  132. Guangxi Medical University Cancer Hospital

    广西医科大学附属肿瘤医院Nanning

    10 papers led
    No open trial led
  133. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    10 papers led
    No open trial led
  134. 10 papers led
  135. 10 papers led
    No open trial led
  136. 9 papers led
    No open trial led
  137. 9 papers led
    No open trial led
  138. 9 papers led
    No open trial led
  139. 9 papers led
    No open trial led
  140. 9 papers led
    No open trial led
  141. 9 papers led
    No open trial led
  142. Shanghai Ninth People's Hospital

    上海交通大学医学院附属第九人民医院Shanghai

    9 papers led
    No open trial led
  143. 9 papers led
    No open trial led
  144. Tongji Hospital

    同济大学附属同济医院Shanghai

    9 papers led
    No open trial led
  145. West China Second University Hospital

    四川大学华西第二医院Chengdu

    9 papers led
    No open trial led
  146. 9 papers led
    No open trial led
  147. 8 papers led
    No open trial led
  148. 8 papers led
    No open trial led
  149. 8 papers led
  150. 8 papers led
    No open trial led
  151. 8 papers led
    No open trial led
  152. Hangzhou First People's Hospital

    杭州市第一人民医院Hangzhou

    8 papers led
    No open trial led
  153. Shanghai Sixth People's Hospital

    上海市第六人民医院Shanghai

    8 papers led
    No open trial led
  154. Yichang Central People's Hospital

    宜昌市中心人民医院Yichang

    8 papers led
    No open trial led
  155. 7 papers led
    No open trial led
  156. Changhai Hospital

    海军军医大学第一附属医院(长海医院)Shanghai

    7 papers led
    No open trial led
  157. 7 papers led
    No open trial led
  158. 7 papers led
    No open trial led
  159. Xi'an Children's Hospital

    西安市儿童医院Xi'an

    7 papers led
    No open trial led
  160. Yidu Central Hospital

    潍坊市益都中心医院Weifang

    7 papers led
    No open trial led
  161. 6 papers led
    No open trial led
  162. 6 papers led
    No open trial led
  163. 6 papers led
    No open trial led
  164. 6 papers led
    No open trial led
  165. Beijing Ditan Hospital, Capital Medical University

    首都医科大学附属北京地坛医院Beijing

    5 papers led
    No open trial led
  166. 5 papers led
    No open trial led
  167. Huai'an First People's Hospital

    淮安市第一人民医院Huai'an

    5 papers led
    No open trial led
  168. 4 papers led
    No open trial led
  169. 4 papers led
    No open trial led
  170. 3 papers led
  171. Shanghai Proton and Heavy Ion Center

    上海市质子重离子医院Shanghai

    2 papers led
    No open trial led
  172. Third Affiliated Hospital of Zhejiang Chinese Medical University

    浙江中医药大学附属第三医院(浙江省中山医院)Hangzhou

    2 papers led
    No open trial led
  173. Yishui Central Hospital

    临沂市中心医院Linyi

    2 papers led
    No open trial led
  174. Beijing Sanbo Brain Hospital

    北京三博脑科医院Beijing

    1 paper led
    No open trial led
  175. Fourth Affiliated Hospital of Soochow University

    苏州大学附属第四医院(独墅湖医院)Suzhou

    1 paper led
  176. Hebei Yanda Lu Daopei Hospital

    河北燕达陆道培医院Langfang

    1 paper led
    No open trial led
  177. Jilin Cancer Hospital

    吉林省肿瘤医院Changchun

    1 paper led
    No open trial led
  178. 1 paper led
    No open trial led
  179. 1 paper led
  180. 1 paper led
    No open trial led
  181. 0 papers led
    No open trial led
  182. Fuda Cancer Hospital

    广州复大肿瘤医院Guangzhou

    0 papers led
    No open trial led
  183. 0 papers led
  184. 0 papers led
    No open trial led
  185. 0 papers led
    No open trial led
  186. 0 papers led
  187. 0 papers led
    No open trial led

By university or health system 59

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Capital Medical University

    首都医科大学Beijing

    436 papers led
    6 hospitals
  2. Central South University (Xiangya)

    中南大学湘雅Changsha

    228 papers led
    6 hospitals
  3. Fudan University

    复旦大学Shanghai

    216 papers led
    6 hospitals
  4. Sichuan University (West China)

    四川大学华西Chengdu

    192 papers led
    4 hospitals
  5. Zhengzhou University

    郑州大学Zhengzhou

    186 papers led
    6 hospitals
  6. Nanjing Medical University

    南京医科大学Nanjing

    176 papers led
    6 hospitals
  7. Soochow University

    苏州大学Suzhou

    174 papers led
    6 hospitals
  8. Southern Medical University

    南方医科大学Guangzhou

    154 papers led
    6 hospitals
  9. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    151 papers led
    5 hospitals
  10. Sun Yat-sen University

    中山大学Guangzhou

    148 papers led
    6 hospitals
  11. Shandong University

    山东大学Jinan

    143 papers led
    6 hospitals
  12. Wuhan University

    武汉大学Wuhan

    141 papers led
    3 hospitals
  13. China Medical University (Shenyang)

    中国医科大学Shenyang

    136 papers led
    6 hospitals
  14. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    123 papers led
    6 hospitals
  15. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    122 papers led
    4 hospitals
  16. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    120 papers led
    6 hospitals
  17. Tianjin Medical University

    天津医科大学Tianjin

    113 papers led
    5 hospitals
  18. Harbin Medical University

    哈尔滨医科大学Harbin

    109 papers led
    4 hospitals
  19. Xi'an Jiaotong University

    西安交通大学Xi'an

    96 papers led
    6 hospitals
  20. Xuzhou Medical University

    徐州医科大学Xuzhou

    96 papers led
    6 hospitals
  21. Shandong First Medical University

    山东第一医科大学Jinan

    92 papers led
    6 hospitals
  22. Jilin University

    吉林大学Changchun

    91 papers led
    3 hospitals
  23. Air Force Medical University

    空军军医大学Xi'an

    90 papers led
    6 hospitals
  24. Nanchang University

    南昌大学Nanchang

    88 papers led
    3 hospitals
  25. Fujian Medical University

    福建医科大学Fuzhou

    87 papers led
    6 hospitals
  26. Anhui Medical University

    安徽医科大学Hefei

    73 papers led
    6 hospitals
  27. Chongqing Medical University

    重庆医科大学Chongqing

    71 papers led
    5 hospitals
  28. Army Medical University

    陆军军医大学Chongqing

    68 papers led
    3 hospitals
  29. Guangzhou Medical University

    广州医科大学Guangzhou

    68 papers led
    6 hospitals
  30. Hebei Medical University

    河北医科大学Shijiazhuang

    65 papers led
    3 hospitals
  31. 63 papers led
    1 hospital
  32. Wenzhou Medical University

    温州医科大学Wenzhou

    61 papers led
    6 hospitals
  33. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    56 papers led
    1 hospital
  34. Qingdao University

    青岛大学Qingdao

    53 papers led
    6 hospitals
  35. Nanjing University

    南京大学Nanjing

    50 papers led
    3 hospitals
  36. Peking University Health Science Center

    北京大学医学部Beijing

    50 papers led
    5 hospitals
  37. Jinan University

    暨南大学Guangzhou

    47 papers led
    6 hospitals
  38. Shenzhen University

    深圳大学Shenzhen

    45 papers led
    6 hospitals
  39. Chongqing University

    重庆大学Chongqing

    42 papers led
    4 hospitals
  40. Tongji University

    同济大学Shanghai

    42 papers led
    6 hospitals
  41. Guangxi Medical University

    广西医科大学Nanning

    41 papers led
    6 hospitals
  42. Guizhou Medical University

    贵州医科大学Guiyang

    40 papers led
    6 hospitals
  43. Xiamen University

    厦门大学Xiamen

    39 papers led
    3 hospitals
  44. Southwest Medical University

    西南医科大学Luzhou

    38 papers led
    1 hospital
  45. 34 papers led
    3 hospitals
  46. Kunming Medical University

    昆明医科大学Kunming

    33 papers led
    6 hospitals
  47. Nantong University

    南通大学Nantong

    28 papers led
    1 hospital
  48. Shantou University Medical College

    汕头大学医学院Shantou

    26 papers led
    1 hospital
  49. Xinjiang Medical University

    新疆医科大学Urumqi

    26 papers led
    5 hospitals
  50. Naval Medical University

    海军军医大学Shanghai

    20 papers led
    5 hospitals
  51. Ningxia Medical University

    宁夏医科大学Yinchuan

    20 papers led
    1 hospital
  52. University of Chinese Academy of Sciences

    中国科学院大学Beijing

    19 papers led
    2 hospitals
  53. 16 papers led
    6 hospitals
  54. Jiangnan University

    江南大学Wuxi

    15 papers led
    1 hospital
  55. Guangdong Medical University

    广东医科大学Zhanjiang

    11 papers led
    3 hospitals
  56. Guilin Medical University

    桂林医学院Guilin

    10 papers led
    1 hospital
  57. Bengbu Medical University

    蚌埠医科大学Bengbu

    7 papers led
    1 hospital
  58. Guangdong Pharmaceutical University

    广东药科大学Guangzhou

    6 papers led
    1 hospital
  59. Chengdu University

    成都大学Chengdu

    5 papers led
    1 hospital

103

open trials on glioma in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with at least one listed hospital as lead sponsor or site. 74 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07243340

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  2. Recruiting
    A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07297212

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Shanghai, Shenzhen, Wuhan

  3. Recruiting
    Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07450872

    Age 8 years to 18 years (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  4. Recruiting
    Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade Glioma
    Phase
    Phase 1
    Started
    2026-02
    Posted
    Registry
    NCT07480941

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  5. Recruiting
    A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07501559

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  6. Recruiting
    Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07511725

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  7. Recruiting
    Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07551336

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  8. Recruiting
    NK Cell Therapy for Malignant Solid Brain Tumors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07552233

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Third Hospital; 1 listed hospital as study siteBeijing, Zhengzhou

  9. Recruiting
    Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07552467

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  10. Recruiting
    Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07584499

    Age 2 years to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  11. Recruiting
    A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07589257

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  12. Recruiting
    Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07608003

    Age not stated (registered criteria)

    Led by Xiangya HospitalChangsha

  13. Recruiting
    Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07648823

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing

  14. Recruiting
    [177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07655869

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing

  15. Recruiting
    A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07678684

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  16. Recruiting
    A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07710690

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesShanghai, Wuhan, Xi'an

  17. Recruiting
    A Phase I Clinical Study of YN003 in the Treatment of Glioma
    Phase
    Phase 1
    Started
    2026-10
    Posted
    Registry
    NCT07929909

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  18. Recruiting
    Prospective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular Classification
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07940231

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  19. Recruiting
    5-Aminolevulinic Acid for Photodynamic Diagnosis of Malignant Glioma
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06160492

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  20. Recruiting
    A Phase 2 Study of HX301 in Patients with High-grade Giloma
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06703255

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  21. Recruiting
    BC008-1A Injection for Recurrent CNS WHO G4 Glioma
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06773481

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  22. Recruiting
    Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06818331

    Age 18 years to 70 years (registered criteria)

    Led by Third Affiliated hospital of Zhejiang Chinese Medical University; 1 listed hospital as study siteHangzhou

  23. Recruiting
    Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06831773

    Age 14 years to 80 years (registered criteria)

    Led by Gansu Wuwei Tumor HospitalWuwei

  24. Recruiting
    Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06902350

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changchun

  25. Recruiting
    PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT06914427

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  26. Recruiting
    Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06936046

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  27. Recruiting
    Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07025018

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  28. Recruiting
    Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
    Phase
    Early phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07067905

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  29. Recruiting
    A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07093814

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shenzhen, Xi'an, Zhuhai

  30. Recruiting
    Allogeneic γδT Cells in Glioblastoma
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT07144735

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Third Hospital; 1 listed hospital as study siteBeijing, Zhengzhou

  31. Recruiting
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
    Phase
    Phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07193628

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  32. Recruiting
    Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07193654

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  33. Recruiting
    AI-assisted Diagnosis of Malignant Brain Tumors
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07198256

    Age 18 years to 100 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou

  34. Recruiting
    Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07263711

    Age 18 years to 100 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  35. Recruiting
    A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07306299

    Age 16 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  36. Recruiting
    Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07405372

    Age 18 years to Not stated (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  37. Recruiting
    Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
    Phase
    Early phase 1
    Started
    2025-01
    Posted
    Registry
    NCT07538128

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  38. Recruiting
    Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07670026

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  39. Recruiting
    Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients
    Phase
    N/A
    Started
    2024-05
    Posted
    Registry
    NCT05990556

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  40. Recruiting
    A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial
    Phase
    N/A
    Started
    2024-02
    Posted
    Registry
    NCT06215495

    Age 18 years to 65 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  41. Recruiting
    Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06327451

    Age 18 years to 60 years (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  42. Recruiting
    Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma
    Phase
    Phase 3
    Started
    2024-04
    Posted
    Registry
    NCT06330337

    Age 18 years to 70 years (registered criteria)

    Led by Third Affiliated hospital of Zhejiang Chinese Medical University; 1 listed hospital as study siteHangzhou

  43. Recruiting
    Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06482905

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  44. Recruiting
    A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06598787

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  45. Recruiting
    Hypofractionated Radiotherapy
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06740955

    Age 18 years to 70 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  46. Recruiting
    Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
    Phase
    N/A
    Started
    2024-03
    Posted
    Registry
    NCT06747728

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  47. Recruiting
    Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients
    Phase
    Early phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06757153

    Age 18 years to Not stated (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  48. Recruiting
    A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma
    Phase
    Phase 1/Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT07599371

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  49. Recruiting
    SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05303519

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Shanghai

  50. Recruiting
    Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
    Phase
    Phase 1
    Started
    2023-09
    Posted
    Registry
    NCT05577091

    Age 18 years to 70 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  51. Recruiting
    Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
    Phase
    Not given
    Started
    2023-01
    Posted
    Registry
    NCT05672043

    Age 0 years to 18 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  52. Recruiting
    Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
    Phase
    Phase 1
    Started
    2023-01
    Posted
    Registry
    NCT05717699

    Age 1 year to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  53. Recruiting
    Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
    Phase
    Phase 1
    Started
    2023-01
    Posted
    Registry
    NCT05717712

    Age 1 year to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  54. Recruiting
    Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
    Phase
    Not given
    Started
    2023-09
    Posted
    Registry
    NCT05968053

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  55. Recruiting
    Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
    Phase
    Not given
    Started
    2023-09
    Posted
    Registry
    NCT06002711

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  56. Recruiting
    Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
    Phase
    Phase 1/Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT06018363

    Age 18 years to 70 years (registered criteria)

    Led by Fourth Affiliated Hospital of Soochow UniversitySuzhou

  57. Recruiting
    Tumor Vaccines for Solid Tumors
    Phase
    Not given
    Started
    2023-10
    Posted
    Registry
    NCT06102837

    Age not stated (registered criteria)

    Led by Huashan HospitalShanghai

  58. Recruiting
    The Effects of Anesthetics on Brain Network Connectivity in Patients With Supratentorial Glioma
    Phase
    Not given
    Started
    2023-08
    Posted
    Registry
    NCT06138340

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  59. Recruiting
    The Role of B7-H4 in Tumor Vaccine
    Phase
    Not given
    Started
    2023-11
    Posted
    Registry
    NCT06156150

    Age 18 years to 80 years (registered criteria)

    Led by Huashan HospitalShanghai

  60. Recruiting
    Recurrent High Grade Glioma Treated by LITT
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT06161610

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 7 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Shanghai, Wuhan, Zhengzhou

  61. Recruiting
    The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06220552

    Age 18 years to Not stated (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  62. Recruiting
    Clinical Study of Oncolytic Virus in Glioblastoma
    Phase
    Phase 1/Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT07145047

    Age 18 years to 70 years (registered criteria)

    Led by Mianyang Central HospitalMianyang

  63. Recruiting
    Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05512351

    Age 18 years to Not stated (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  64. Recruiting
    Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
    Phase
    Not given
    Started
    2022-01
    Posted
    Registry
    NCT05859659

    Age 18 years to 90 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  65. Recruiting
    A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT06173076

    Age 18 years to 100 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  66. Recruiting
    JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
    Phase
    Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT06595186

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  67. Recruiting
    A Registry-Based Cohort Study on the Clinical Outcomes of Spinal Cord Glioma Resection Via the Dorsolateral Sulcus Approach
    Phase
    Not given
    Started
    2022-01
    Posted
    Registry
    NCT07066475

    Age 3 years to 75 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  68. Recruiting
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-04
    Posted
    Registry
    NCT04794972

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Shenzhen, Xi'an

  69. Recruiting
    Study of GC101 TIL in Brain Glioma (Soochow2)
    Phase
    Early phase 1
    Started
    2021-05
    Posted
    Registry
    NCT04943913

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

  70. Recruiting
    Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery
    Phase
    Phase 2/Phase 3
    Started
    2018-04
    Posted
    Registry
    NCT04316039

    Age 18 years to 70 years (registered criteria)

    Led by West China HospitalChengdu

  71. Recruiting
    MR Based Survival Prediction of Glioma Patients Using Artificial Intelligence
    Phase
    Not given
    Started
    2017-01
    Posted
    Registry
    NCT04215211

    Age 1 year to 90 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  72. Recruiting
    Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence
    Phase
    Not given
    Started
    2017-01
    Posted
    Registry
    NCT04215224

    Age 1 year to 90 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  73. Recruiting
    MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
    Phase
    Not given
    Started
    2017-01
    Posted
    Registry
    NCT04217018

    Age 1 year to 95 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  74. Recruiting
    Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
    Phase
    Not given
    Started
    2017-01
    Posted
    Registry
    NCT04217044

    Age 1 year to 95 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  75. Recruiting
    Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion
    Phase
    N/A
    Started
    2017-01
    Posted
    Registry
    NCT05990244

    Age 18 years to 80 years (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  76. Recruiting
    Integrative Analysis of Human Glioblastoma Multiforme
    Phase
    Not given
    Started
    2016-01
    Posted
    Registry
    NCT03005132

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  77. Recruiting
    Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
    Phase
    Not given
    Started
    2013-08
    Posted
    Registry
    NCT07379463

    Age 18 years to 90 years (registered criteria)

    Led by Tianjin Medical University General Hospital; 2 listed hospitals as study sitesHefei, Qingdao, Tianjin

  78. Not yet recruiting
    A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07455045

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  79. Not yet recruiting
    Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07469735

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  80. Not yet recruiting
    A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07472790

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  81. Not yet recruiting
    IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07481721

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  82. Not yet recruiting
    EEG-Guided Cognitive Function Preservation in Patients With Brain Tumors
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07699172

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Huanhu HospitalTianjin

  83. Not yet recruiting
    Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07758062

    Age 18 years to 69 years (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  84. Not yet recruiting
    Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07831187

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  85. Not yet recruiting
    IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma
    Phase
    Phase 3
    Started
    2026-12
    Posted
    Registry
    NCT07869524

    Age 3 years to 18 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  86. Not yet recruiting
    Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
    Phase
    Phase 2/Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07873996

    Age 18 years to 65 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  87. Not yet recruiting
    Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
    Phase
    Phase 1
    Started
    2025-01
    Posted
    Registry
    NCT06737146

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  88. Not yet recruiting
    Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT06939400

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  89. Not yet recruiting
    FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07004075

    Age 2 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  90. Not yet recruiting
    Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children
    Phase
    Not given
    Started
    2025-07
    Posted
    Registry
    NCT07020052

    Age 3 years to 18 years (registered criteria)

    Led by Union HospitalWuhan

  91. Not yet recruiting
    Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
    Phase
    Early phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07244666

    Age 19 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  92. Not yet recruiting
    Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT06368934

    Age 18 years to 80 years (registered criteria)

    Led by Huashan Hospital; 1 listed hospital as study siteShanghai

  93. Not yet recruiting
    Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
    Phase
    Early phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06396481

    Age 4 years to Not stated (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  94. Not yet recruiting
    Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT05540275

    Age 18 years to Not stated (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  95. Not yet recruiting
    Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
    Phase
    Phase 2
    Started
    2023-05
    Posted
    Registry
    NCT05842746

    Age 18 years to 70 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  96. Not yet recruiting
    Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05502991

    Age 18 years to Not stated (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  97. Not yet recruiting
    Study on Gene Evolution in Glioma Under Stress Therapy
    Phase
    Not given
    Started
    2022-12
    Posted
    Registry
    NCT05512325

    Age 18 years to 75 years (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  98. Not yet recruiting
    Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma
    Phase
    Not given
    Started
    2022-12
    Posted
    Registry
    NCT05532969

    Age 18 years to 75 years (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  99. Not yet recruiting
    Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
    Phase
    Not given
    Started
    2022-12
    Posted
    Registry
    NCT05541042

    Age 18 years to Not stated (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  100. Enrolling by invitation
    Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT07126990

    Age 18 years to 80 years (registered criteria)

    Led by Sanbo Brain HospitalBeijing

  101. Enrolling by invitation
    Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06690216

    Age 18 years to Not stated (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  102. Enrolling by invitation
    Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06763965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  103. Enrolling by invitation
    The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
    Phase
    Phase 1
    Started
    2023-12
    Posted
    Registry
    NCT06616727

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Additional research sources

Read the linked papers and reports

Where these numbers come from

Papers

7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 18 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions